Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection
- Conditions
- HIV InfectionsSexually Transmitted Diseases
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- The Miriam Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04240509
- Locations
- 🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
- Conditions
- Healthy
- Interventions
- Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 16
- Registration Number
- NCT04236453
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 599
- Registration Number
- NCT04233879
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc. ( Site 5624), Los Angeles, California, United States
🇺🇸The Kinder Medical Group ( Site 5615), Miami, Florida, United States
🇺🇸University of Pennsylvania ( Site 5630), Philadelphia, Pennsylvania, United States
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 643
- Registration Number
- NCT04223791
- Locations
- 🇫🇷
Hopital Edouard Herriot ( Site 3126), Lyon, Ain, France
🇫🇷CHU de Nice Hopital Archet 1 ( Site 3103), Nice, Alpes-Maritimes, France
🇮🇹A.O.R.N. dei Colli - Ospedale Cotugno ( Site 3507), Napoli, Italy
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
- Conditions
- HIV PreventionTransgender Health
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 48
- Registration Number
- NCT04050371
- Locations
- 🇺🇸
San Francisco AIDS foundation, San Francisco, California, United States
Combination Antiretroviral Therapy (cART) for PBC
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo Oral Capsule [CEBOCAP]
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 37
- Registration Number
- NCT03954327
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇨🇦University of Montreal, Montréal, Quebec, Canada
Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
- Conditions
- HIV/AIDS
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 10
- Registration Number
- NCT03917420
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men
- Conditions
- Adherence, MedicationRisk BehaviorPre-Exposure ProphylaxisHIV Prevention
- Interventions
- Other: DOT Diary mobile app
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Public Health Foundation Enterprises, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03771638
- Locations
- 🇺🇸
Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States
🇺🇸Emory University, School of Public Health, Atlanta, Georgia, United States
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
- Conditions
- HIV-1/HBV Co-Infection
- Interventions
- Drug: B/F/TAFDrug: Placebo to match DTGDrug: Placebo to match F/TDFDrug: Placebo to match B/F/TAF
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 244
- Registration Number
- NCT03547908
- Locations
- 🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
🇨🇳Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸CHUVI - Hospital Universitario Alvaro Cunqueiro, Vigo, Spain
RESIST-2: 2nd-line ART for HIV-2 Infection
- Conditions
- HIV-2 Infection
- Interventions
- Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 152
- Registration Number
- NCT03394196
- Locations
- 🇸🇳
Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann, Dakar, Senegal
🇸🇳Centre de Sante de Ziguinchor, Ziguinchor, Casamance, Senegal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.